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Stargardt disease is caused by variants in the ABCA4 gene, a significant part of which are noncanonical splice site (NCSS)
variants. In case a gene of interest is not expressed in available somatic cells, small genomic fragments carrying potential
disease-associated variants are tested for splice abnormalities using in vitro splice assays. We recently discovered that
when using small minigenes lacking the proper genomic context, in vitro results do not correlate with splice defects observed
in patient cells. We therefore devised a novel strategy in which a bacterial artificial chromosome was employed to generate
midigenes, splice vectors of varying lengths (up to 11.7 kb) covering almost the entire ABCA4 gene. These midigenes were used
to analyze the effect of all 44 reported and three novel NCSS variants on ABCA4 pre-mRNA splicing. Intriguingly, multi-
exon skipping events were observed, as well as exon elongation and intron retention. The analysis of all reported NCSS var-
iants in ABCA4 allowed us to reveal the nature of aberrant splicing events and to classify the severity of these mutations based
on the residual fraction of wild-type mRNA. Our strategy to generate large overlapping splice vectors carrying multiple
exons, creating a toolbox for robust and high-throughput analysis of splice variants, can be applied to all human genes.
[Supplemental material is available for this article.]
Technological advancements have enabled the cost-effective
detection of sequence variations in human genomes (Carss et al.
2017). Millions of single-nucleotide variants (SNVs) have been re-
ported per individual, many thousands of which are rare and can
be involved in rare monogenic disorders. Unfortunately, the enor-
mous progress made in SNV detection has not been accompanied
by the development of functional assays to investigate the effects
of SNVs in a robustmanner. Although it is very challenging to pre-
dict the effect of missense variants on protein function, character-
izing putative splice variants is feasible. In the absence of patient
cells, or if the gene of interest is not expressed in available somatic
cells, in vitro splice assays arewidely used. In these assays, small ge-
nomic fragments carrying potential disease-associated variants are
tested for splice abnormalities. However, with the increasing
detection of noncoding variants located within large introns, it
is apparent that minigene assays are inadequate for testing the ef-
fects of deep-intronic variants without an intact genomic context,
i.e., flanking exons and cis-acting elements that influence exon
recognition.
The ATP-binding cassette transporter type A4 (ABCA4) is a
128-kb gene consisting of 50 exons and characterized by retina-
specific expression (Allikmets et al. 1997). It encodes a multido-
main transmembrane protein localized at the outer segments of
photoreceptor cells (Sun and Nathans 1997; Molday et al. 2000).
The estimated incidence of individuals with ABCA4-associated in-
herited retinal diseases is 1/10,000 (Blacharski 1988). ABCA4 vari-
ants have been observed in the vast majority (95%) of patients
with autosomal recessive (ar) Stargardt disease (STGD1), ∼30% of
patients with ar cone-rod dystrophy (CRD) and ∼5% of patients
with ar panretinal dystrophy (Cremers et al. 1998; Maugeri et al.
1999, 2000). The phenotypic heterogeneity observed in individu-
als with ABCA4-associated retinal dystrophies can be explained by
a genotype-phenotype correlationmodel, inwhich the residual ac-
tivity of the mutant ABCA4 protein determines the clinical out-
come. Typical STGD1 patients are usually characterized by a
combination of a severe and a mild variant or two moderately
severe variants, while patients affected bymore severe phenotypes
such as CRD and panretinal dystrophy carry a severe and a moder-
ately severe variant or two severe variants, respectively (Cremers
et al. 1998; Maugeri et al. 1999, 2000).
In order to provide an accurate prognosis for people with
ABCA4-associated disease, it is essential to assess the functional
consequences of all variants. Thus far, functional studies have
been limited to selected missense variants that were studied at
the protein level (Sun et al. 2000; Suarez et al. 2002; Quazi and
Molday 2013), and only a small number of splice site variants
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have been examined (Rivera et al. 2000; Shroyer et al. 2001;
Wiszniewski et al. 2005; Schulz et al. 2017).While the high impact
of protein-truncating ABCA4 variants (nonsense, frameshift, ca-
nonical splice site variants) is clear, the effect of noncanonical
splice site (NCSS) variants still remains largely unknown. These
are either exonic or intronic variants located at the splice donor
sites and splice acceptor sites. Intronic NCSS variants at splice
donor sites are mostly situated at positions +3 to +6 downstream
from exons, while intronic NCSS variants at splice acceptor sites
are located at positions −14 to −3 upstream of exons. Exonic
ABCA4 NCSS variants can only be found within the first or the
last two nucleotides of an exon (Cornelis et al. 2017), which agrees
with in silico predictions (Shapiro and Senapathy 1987).
Very recently, all publishedABCA4 variants from3928 retinal
dystrophy cases were collected in a Leiden Open Variation
Database (www.LOVD.nl/ABCA4), and an in silico pathogenicity
assessment was provided for the 913 unique variants (Cornelis
et al. 2017). Forty-four NCSS variants were identified that together
account for 10% of all published ABCA4 alleles associated with
STGD1 (Cornelis et al. 2017), and 41% of all ABCA4 alleles in pa-
tients with STGD1 from the Radboudumc in Nijmegen (N Bax, S
Lambertus, FPM Cremers, and CB Hoyng, unpubl.). In silico pro-
grams assessing the pathogenicity of NCSS variants cannot always
predict the effect of pre-mRNA splicing. For instance, the second
most frequent ABCA4 variant, c.5461−10T>C, was predicted to
be a mild variant, but it led to skipping exon 39, or exons 39 and
40, when tested in patient-derived photoreceptor precursor cells
and a minigene assay (Sangermano et al. 2016), and in fibroblasts
(Aukrust et al. 2017). It thereby could be classified as a severe
ABCA4 variant.
In view of the large number of NCSS variants in ABCA4 with
unknown functional effect, we designed a protocol to prepare size-
able multiple-exon ‘midigenes’ in order to test the consequences
of all ABCA4 NCSS variants in their ‘natural context,’ resulting
in a robust in vitro splice assay system.We generated a nearly com-
plete library of overlapping wild-type midigenes from the ABCA4
gene, which allowed us to systematically assess the effect of 47
NCSS variants on RNA splicing.
Results
A large minigene enables accurate RNA analysis of the
noncanonical splice site variant c.5714+5G>A
Previous genotype-phenotype studies in a large family with indi-
viduals showing pseudodominant ar retinitis pigmentosa (RP)
due to a homozygous c.4539+1G>T ABCA4 splice variant, or ar
CRD due to compound heterozygous c.4539+1G>T and c.5714
+5G>A ABCA4 variants, led to the hypothesis that the NCSS vari-
ant c.5714+5G>A had a moderately severe effect (Cremers et al.
1998). Intriguingly, HEK293T cells transfected with small wild-
type and mutant minigenes that contained only exon 40 showed
partial skipping of exon 40 for the wild-type construct and full
exon 40 skipping due to the c.5714+5G>A variant (Fig. 1A).
Since our previous work (Cremers et al. 1998) and recent statistical
analysis (Cornelis et al. 2017) suggested this variant had a moder-
ate or mild effect on ABCA4 function, respectively, it seemed un-
likely that the c.5714+5G>A variant would result in full exon 40
skipping. We noticed a similar artifact while studying the effect
of another NCSS variant, c.5461−10T>C (Sangermano et al.
2016), so we hypothesized that the rhodopsin (RHO) exon 3 splice
donor site and RHO exon 5 splice acceptor site are relatively strong
(Human Splicing Finder scores of 87.5 and 90.7, respectively), re-
sulting in erroneous exon 40 skipping. When we used larger mini-
genes containing exons 39 through 41, the erroneous exon 40
skipping in the wild-type construct was not observed anymore,
and the mutant construct showed normal RNA product in addi-
tion to the exon 40 skipping product (Fig. 1B), as expected for a
moderately severe variant.
Generation of ABCA4 wild-type midigene library
In view of these results and our goal to robustly test all reported
NCSS variants identified in ABCA4, we generated multi-exon
splice vectors using DNA from a bacterial artificial chromosome
(BAC) clone (CH17-325O16) spanning the entire ABCA4 gene.
In this way, a library of 29 overlapping wild-type midigenes
(BA1–BA29) was generated (Fig. 2) by PCR amplification of frag-
ments that were cloned in a Gateway-adapted vector containing
the RHO exons 3, 4, and 5 (pCI-NEO-RHO) with the recombination
sequences located between RHO exons 3 and 4 and between exons
4 and 5. The insert sizes for these constructs ranged from 4.0 to
11.7 kb, with, on average, three ABCA4 exons per construct. The
maximal capacity of the vector is 12 kb. Hereafter, the pCI-NEO-
RHO BA clones will be denoted as BA# clones.
ABCA4 exons 1 and 50 were not contained in these clones, as
they lack a splice acceptor and donor site, respectively. Due to dif-
ficulties in long-range PCR amplification at the 3′ end of the gene,
wewere also unable to amplify a genomic fragment containing ex-
ons 46–49. Instead, regular minigenes were generated for exons 48
(MG30) and 49 (MG31) using control genomic DNA as template.
The midi- and minigenes together covered ∼92% of the 128-kb
ABCA4 gene and 48 out of 50 exons (Fig. 2).
In all constructs, eachABCA4 exonwas flanked by at least one
upstream and one downstream ABCA4 exon, with the exception
of BA1, BA4, BA6, BA8, BA10, BA29, MG30, and MG31. For
Figure 1. Large minigene enables accurate RNA analysis of the ABCA4
noncanonical splice site variant c.5714+5G>A. (A) Minigene containing
the genomic region encompassing ABCA4 exon 40 (MG_ex40, black rect-
angle) and flanked by rhodopsin (RHO) exons 3 and 5 (open boxes) was
designed to investigate the effect of the noncanonical splice site variant
c.5714+5G>A. Reverse-transcription polymerase chain reaction (RT-PCR)
performed using primers (open arrowheads) targeting RHO exons 3 and
5 showed an expected 404-bp wild-type fragment and a 274-bp fragment
corresponding to exon 40 skipping (Δ) in control minigene (+5G) and full
exon 40 skipping in mutant minigene (+5A). (B) Larger minigene contain-
ing the genomic region encompassing ABCA4 exons 39–41 (MG_ex39–
41) was designed to investigate the same variant. RT-PCR using primers
(black arrowheads) targeting exons 39 and 41 showed a single 260-bp
wild-type fragment in the control minigene, while in the mutant minigene
fragments of 260 and 130 bp corresponding to wild-type and exon 40
skipping were found.
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constructs BA4, BA6, BA8, and BA10, the limitation was due to the
large sizes of intron 6 (15.4 kb) and 11 (14.4 kb). BA5 and BA9 did
not contain any exon, as they were generated to cover the middle
parts of introns 6 and 11, respectively.
Sequence analysis of the wild-type BA clones revealed many
polymorphisms but no deleterious variants due to the PCR ampli-
fication of the insert when compared to the human genome refer-
ence GRCh37/hg19 assembly. Nevertheless, despite the use of a
proofreading high-fidelity DNA polymerase, we found minor se-
quence variations (Supplemental Table S1).
Selection of ABCA4 noncanonical splice site variants
The list of the 47 analyzed NCSS variants, their allelic frequencies,
and predicted effect on splicing can be found in Supplemental
Table S2. The majority of these variants (70%, n = 33) are located
in noncoding elements; 30% (n = 14) are located in coding regions.
Highly mutated intronic positions at the splice donor site were at
the +5 (n = 12) and +3 (n = 6) positions.We did not observe signifi-
cant “hotspots” at the splice acceptor site, although positions −3
and −10 were most frequently mutated (n = 3 each).
Generation of mutant midigenes
Eighteen BA clones were used to insert 46 NCSS variants (Fig. 2;
Supplemental Fig. S1). Fifteen clones carry at least two flanking
ABCA4 exons surrounding the tested NCSS variant, thereby allow-
ing RT-PCRusingABCA4 primers instead ofRHO primers. For three
variants, this was not possible. c.160+5G>C and c.5312+3A>T
were analyzed using a combination of a RHO exon 3 forward
Figure 2. Overview of the wild-type midigene splice constructs of ABCA4 and locations of all 47 noncanonical splice site variants. Exons are represented
here as black rectangles. Employing bacterial artificial chromosome DNA and Gateway sequence-tagged primers, we amplified 29 genomic fragments and
cloned these into the pCI-NEO-RHOGateway-adapted vector (BA1–BA29). Genomic DNA from control persons (MG30 andMG31) and a patient carrying
c.6729+5_6729+19del (MG30) were used to clone wild-type and mutant fragments.
Sangermano et al.
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primer with ABCA4 exons 4 or 40 reverse primers, respectively. As
c.768G>T resided in BA4, RT-PCR could only be performed using
RHO exons 3 and 5 primers.
Eleven BA clones and MG31 were not used for mutagenesis
purposes in this study. For variant c.6729+5_+19del, we did not
perform mutagenesis as the wild-type and mutant minigenes
weremade using genomicDNA fromapatient carrying this variant
in a heterozygous manner.
Splice defects due to noncanonical splice site variants
We provided experimental evidence of splice defects for 44 out of
47NCSS variants. For the RT-PCR control, cDNA from18wild-type
BA clones was used (Fig. 2). Upon RT-PCR, 15 wild-type BA clones
showed a single band corresponding to the expected splicing pat-
tern, whereas BA1, BA12, and BA26 showed extra bands corre-
sponding to alternative splice products (Supplemental Fig. S2). A
comprehensive overview of all the splice assays for the 47 NCSS
variants described in this study, as well as their sequencing analy-
sis, can be found in Supplemental Figures S2 and S3. Repre-
sentative results for nine variants are described below (Fig. 3;
Supplemental Fig. S3).
Variants c.160+5G>C, c.161G>T, c.302+4A>G, and c.303
−3C>G were located in or near exons 2 and 4 and were introduced
in BA1 (Figs. 2, 3A–F). Variant c.160+5G>Cwas predicted to signif-
icantly reduce the strength of the exon 2 splice donor site and like-
ly cause exon skipping (Supplemental Table S2). RT-PCR using a
primer at the 5′ side of exon 2 therefore was not useful. Hence,
we used primers in RHO exon 3 and ABCA4 exon 4. The wild-
type BA1 showed two main bands of 399 and 271 bp. Sanger se-
quence analysis showed that these were the expected mRNA frag-
ment and a fragment in which exon 3 was skipped, respectively
(Fig. 3A,B). c.160+5G>C showed a complex splicing pattern, i.e.,
correct and three main aberrant splice products, that after
pGEM-T cloning and Sanger sequencing revealed bands of 305,
285, and 271 bp, which represented the skipping of exon 2, a
14-nt elongation of exon 2 along with skipping of exon 3, and
skipping of exon 3, respectively (Fig. 3A–C). Exon 2 elongation
can be explained by the presence of a cryptic splice donor site
14-nt downstream from the actual splice site. The cryptic donor
site is not shown in Figure 3C as it can only be seen in the genomic
DNA sequence. RT-PCR spanning ABCA4 exons 2–4 showed a
wild-type 289-bp band for BA1. The introduction of variants
c.161G>T and c.302+4A>C both showed a unique 147-bp band
corresponding to skipping of exon 3, while c.303−3C>G showed
two bands of 291 and 149 bp, corresponding to a dinucleotide
elongation of exon 4 and to the same elongation along with the
skipping of exon 3, respectively (Fig. 3D–F). The exon 4 elongation
can be explained by the creation of a cryptic splice acceptor site
due to the C>G change. The cryptic acceptor site is not shown in
Figure 3F as it can only be seen in the genomic DNA sequence.
The skipping of exon 3 in the wild-type BA1 clone probably was
not an artifact, as we also observed exon 3 skipping in human ret-
ina RNA (Supplemental Fig. S2, BA1, panel C).
Variant c.768G>T is the second most frequent NCSS variant
(allele frequency 0.106) in STGD1 cases in the Radboudumc,
Nijmegen (N Bax, S Lambertus, FPM Cremers, and CB Hoyng,
unpubl.). Splice predictions showed a significant weakening of
the exon 6 splice donor site (Fig. 3I). For the wild-type and
c.768G>T mutant BA4 clone, RT-PCR encompassing RHO exons
3 and 5 was performed, which yielded a wild-type band of 472
bp for BA4 and a 35-nt elongation of exon 6 for c.768G>T (Fig.
3G,H), explained by the presence of a cryptic splice donor site
36-nt downstream (Fig. 3I). The reading frame shift results in a pre-
dicted truncated protein, p.(Leu257Valfs∗17). To validate this re-
sult ‘ex vivo,’ we generated photoreceptor precursor cells (PPCs)
from somatic cells of a STGD1 patient carrying c.768G>T in a ho-
mozygous state. RT-PCR analysis of RNA from this patient and of
normal human retina are shown in Supplemental Figure S4. The
PPC results are identical to those observed in the in vitro splice as-
say in HEK293T cells.
The novel variant c.1937+13T>G was not predicted to result
in a splicing defect (Fig. 3L), but surprisingly, in 86% of mRNA
products, a 12-nt elongation of exon 13was observed for BA11 car-
rying c.1937+13T>G (Fig. 3J,K). This led to a premature stop co-
don, resulting in p.(Phe647∗) (Fig. 3L).
For exon 30, the penultimate nucleotide substitutions
c.4538A>G and c.4538A>C were introduced into BA20, and
HEK293T cell transfection resulted in four fragments after
pGEM-T cloning (Fig. 3M). In addition to the correct mRNA (frag-
ment 1), a 30-nt elongation due to the presence of a strong cryptic
intronic splice donor site (fragment 2, Fig. 3M,O), a deletion of 73
nt from the 3′ end of exon 30 (fragment 3, Fig. 3N), and a 30-nt
elongation in combination with a 114-nt deletion from the 5′
end of exon 30 (fragment 4, Supplemental Figs. S2, S3) were found.
Fragments 3 (227 bp) and 4 (216 bp) could not be resolved. The
exon 30 deletions were the result of partially overlapping cryptic
splice donor and acceptor sites, the noncanonical sequences
(AG/GT) of which reside at exonic positions c.4465–4468 (Supple-
mental Fig. S2, BA20, panel D).
Six fragments were observed for c.5898+5del introduced in
BA27, but we were only able to sequence three after pGEM-T clon-
ing: Bands of 717 and 780 bp corresponded to 107-nt and 170-nt
elongations of exon 42 due to the use of cryptic splice donor
sites at positions c.5898+108 and +171, respectively, while a
1104-bp fragment corresponded to the entire retention of intron
42 (Fig. 3P,Q).
Classification of noncanonical splice site variants according to the
splice defects
The percentage of correctly spliced ABCA4 RNA product for
NCSS variants was calculated by using a capillary electrophoresis
system (Fig. 4; Supplemental Table S3; Supplemental Fig. S5).
Three variants, c.4634G>A, c.5196+3_5196+8del, and c.5585
−10T>C, showed 100% correctly splicedABCA4mRNAs.We could
rule out pathogenicity for the last two variants but not for
c.4634G>Ap.(Ser1545Asn), as this variant is significantly enriched
in >3000 Caucasian STGD1 patients compared to the non-Finnish
ExAC population (Cornelis et al. 2017). Sixteen variants showed
between 4.3% and 79.6% normal RNA and were tentatively classi-
fied as severe,moderately severe, andmild, while the remaining 26
NCSS variants did not show any normal RNA and were thus
deemed severe variants. For c.2382+5G>C and c.2588G>C, no
quantification was performed as the wild-type BA12 clone also
showed exon skipping. Based on the Sanger sequence validation,
we were able to annotate all the variants at the RNA level and pre-
dict their effect at the protein level (Table 1).
We correlated the predicted effect of the NCSS variants
with the phenotypes in reported cases and, when the variants
were not present in a homozygous state, with the severity of the
second allele. For 25 of 47 variants, sufficient clinical data were
available, and in all these cases, our predicted effect of the NCSS
Midigene-based splice assays for ABCA4
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Figure 3. Overview of splice defects due to nine noncanonical splice site variants in ABCA4. All wild-type and mutant midigenes were transfected in
HEK293T cells and their RNA subjected to RT-PCR. (A,B) RT-PCR for wild-type and c.160+5G>C mutant BA1 midigene showed complex splicing defects
when using primers in RHO exon 3 and ABCA4 exon 4. Five defects (fragments 2 through 6) were observed next to the wild-type fragment 1. Asterisks
denote fragments for which we obtained no sequence information. The RT-PCR products showed skipping of exon 2, exon 3, or exons 2 and 3. (C)
Sequencing of pGEM-T-cloned fragment 4 revealed a 14-nt insertion due to the activation of a cryptic splice donor site in intron 2 and the absence of
exon 3. The triangle points to the +5G>C variant. (D,E) RT-PCR products of wild-type and mutant BA1 containing NCSS variants residing at splice sites
of exons 3 and 4. Primers in ABCA4 exons 2 and 4 reveal exon 3 skipping and/or exon 4 elongation. Note that the wild-type vector BA1 shows exon 3
skipping (fragment 5), which is more pronounced when using a forward RHO exon 3 primer (A) compared to using a forward ABCA4 exon 2 primer
(D). (F) Sanger sequence of gel-purified fragment 3 shows a 2-nt elongation at the 3′ end of exon 4 due to the activation of a cryptic splice acceptor
site in intron 3. Sanger sequencing results for all fragments without an asterisk are provided in Supplemental Figure S3. (G,H) RT-PCR and Sanger sequenc-
ing of RNA extracted from c.768G>T mutant BA4 midigene showed a 35-nt exon 6 elongation. (I) Human Splice Finder (HSF) splice site scores (blue ar-
rowheads) for wild-type andmutant sites. (J,K) RT-PCR, gel analysis, and Sanger sequencing showed thewild-type product and a 12-nt exon 13 elongation
due to c.1937+13T>G. M and WT denote mutant and wild-type splice products. (L) Details of the exon elongation defect. As represented by the HSF pre-
diction software, the scores of the normal and intronic splice donor sites (SDSs) are not changed due to this variant. Most of the RT-PCR product consists of
the exon elongation which introduces a premature stop-codon. (M–O) Variants at the penultimate position of exon 30 (c.4538A>G and c.4538A>C) re-
sulted in a correctmRNA (fragment 1), a 30-nt exon 30 elongation due to the presence of a strong cryptic intronic splice donor site (fragment 2), a deletion
of 73 nt of the 3′ end of exon 30 (fragment 3), and a 30-nt exon 30 elongation in combinationwith a 114-nt deletion of the 5′ end of exon 30 (fragment 4).
Fragments 3 (227 bp) and 4 (216 bp) could not be resolved. The exon 30 deletions are the results of cryptic splice donor and acceptor sites that overlap at
exonic positions c.4465–4468 (Supplemental Fig. S2, BA20). (P) RT-PCR of BA27 carrying the c.5898+5del variant resulted in at least two exon 42 elon-
gation products of 717 and 780 bp, as well as intron 42 retention. (Q) The exon elongation products were due to the reduction of the strength of the exon
42 splice donor site, as shown with red numbers, in combination with the presence of nearby cryptic intronic splice donor sites with strong predicted
scores. Only HSF and SpliceSiteFinder (SSF)-like scores are provided. Note that SSF-like is the only software that predicts the rare splice donor sites (positions
c.5898+108 and c.5899−23) that contain the canonical GC sequence instead of GU. Intron 42 retention likely is due to the very strong splice donor site
(HSF 98.0) flanking exon 43. The open arrowhead denotes the 1-bp deletion.
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variants correlated with the observed phenotypes (Supplemental
Table S4).
Discussion
Splice site variants cause 15%–20% of human genetic disease
(Matlin et al. 2005), and an increasing number of deep-intronic
variants have been identified through targeted gene sequencing
and whole-genome sequencing (www.dbass.soton.ac.uk) (Buratti
et al. 2011; Carss et al. 2017). Contrary to canonical splice site var-
iants, which in about two-thirds of cases result in exon skipping
(Cheung et al. 2017), the effect of NCSS variants can vary tremen-
dously, depending on the sequence alteration itself and its se-
quence environment. In recent studies, large-scale analyses of
variants in or near consensus splice site sequences were performed
usingminigene constructs containing small exons flanked bymin-
imal intronic sequences (Cheung et al. 2017). The maximum in-
sert size of the tested genomic segments measured 170 bp, as the
analysis of spliced sequences was performed by short-read next-
generation sequencing. Although this type of study enabled
high-throughput analysis of randomly designed splice site se-
quences (Rosenberg et al. 2015) or naturally occurring NCSS vari-
ants (Cheung et al. 2017), the size constraint of the employed
constructs represents a major limitation to fully assess the effect
of NCSS variants. As shownhere, it is important to studyNCSS var-
iants in the context of their upstream or downstream introns and
exons, as their effect often is influenced by other intronic cis-regu-
latory elements or affects exons located at considerable distances.
We have performed a systematic in vitro analysis of all report-
ed and three novel NCSS variants in ABCA4 that are associated
with STGD1 by generatingmidigenes: large,multi-exon splice vec-
tors. Forty-four of 47 variants resulted in splicing defects. Themost
frequently observed defect, seen in 29 (62%) of the NCSS variants,
was single ormulti-exon skipping. For eight (17%) variants, we ob-
served the simultaneous occurrence of different splice defects, e.g.,
exon skipping/elongation, skipping/retention, elongation/reten-
tion, and truncation/elongation. Six
NCSS variants (13%) resulted in exon
elongation.
The majority of NCSS variants (n =
35; 75%) affected the splice donor site.
This concurs with the observation that
the majority (65%) of pseudoexon
mRNA insertions associated with human
diseases also concern the activation of
splice donor sites (www.dbass.soton.ac.
uk) (Buratti et al. 2011). The longer
intronic consensus sequences of splice
acceptor sites (−3 to −14 for splice accep-
tor site vs. +3 to +6 for splice donor site)
in which pyrimidine to pyrimidine sub-
stitutions have relatively little effect on
the predicted splice strengths, may ex-
plain why variants that affect the splice
acceptor site are generally less disruptive.
The severe NCSS defect previously
shown for c.5461−10T>C (exon 39 or
exon 39 and 40 skipping) (Sangermano
et al. 2016) prompted us to investigate
the effect of two similar rare variants,
i.e. c.2919−10T>C and c.5585−10T>C.
We found that c.2919−10T>C resulted in exon skipping in 39%
of the ABCA4 transcripts, while c.5585−10T>C showed no splice
defects. The predicted reductions of the corresponding splice
acceptor site splice scores all were minor. These contrasting results
suggest that the effect of a NCSS variant also depends on the se-
quence context, e.g., the strengths of nearby splice acceptor
and donor sites, the size of the flanking exons, and possibly
exonic and intronic splice enhancer (ESE, ISE) and silencer motifs
(ESS, ISS).
The effect of still unknown sequencemotifs on splicing is also
illustrated by our findings for c.1937+13T>G. This is not a typical
NCSS variant as it is located downstream from the exon 13 splice
donor site consensus sequence. As illustrated in Figure 3, J through
L, this change does not lower the strength of the normal exon 13
splice donor site, nor does it create a stronger predicted down-
stream splice donor site. Nevertheless, it resulted in a 12-nt elonga-
tion of exon 13 and introduced a premature stop codon in 86% of
the transcripts, based on Sanger sequencing. TheAlamut ESEfinder
did not predict this variant to create a splice enhancer (Cartegni
et al. 2003; Smith et al. 2006). Follow-up studies are required to in-
vestigate the nature of this apparently unknown sequence motif
that influences splicing. Importantly, this result also illustrates
that the assessment of rare noncoding variants identified in diag-
nostic testing cannot fully rely on in silico predictions.
The generation of multiple-exon splice constructs in which
most of the introduced NCSS variants were flanked by one or
more upstream and downstream exons allowed us to investigate
the full spectrum of splice defects. This is illustrated by two
+5delG variants, c.3522+5del in Supplemental Figure S2 and
c.5898+5del in Figure 3, P andQ, which not only showedmultiple
exonelongationbut also retentionof introns 23 and42, respective-
ly. The exon elongations could be explained by similarities shared
by both introns, as they both carry multiple strong cryptic splice
donor sites, small downstream introns (intron 23, 1081 bp; intron
42, 494 bp), and strong splice donor sites located at the 3′end of the
following exon. The importance of the presence of the sequence
context was also found for NF1 as the extent of exons 36 and 37
Figure 4. Percentages of remaining normal ABCA4 transcripts due to noncanonical splice site variants
based on capillary electrophoresis system analyses. The percentages of normal ABCA4 transcript for 45
noncanonical splice site variants are represented by black bars. Nineteen variants showed varying frac-
tions (4.3%–100%) of correct ABCA4 mRNA. Four of them also result in missense changes as depicted,
but only p.(Ser1545Asn) and p.(Lys2160Glu) are likely to have an effect on protein function, as significant
amounts of ABCA4 protein will be produced. For the remaining 26 variants (in the square box), no resid-
ual RNA was observed. (#) For this variant, densitometric scanning was performed.
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skipping due to a variant in exon 37 was determined by the pres-
ence of exons 34–38 in the splice construct (Baralle et al. 2006).
The observation that NCSS variants with an effect on RNA
splicing resulted in a maximum of 79.6% of normal RNA leads
us to believe that there may be a threshold for alleles to behave
as ‘mild’ alleles. In our experiments, that threshold is ∼80% (Fig.
4). In cases where there is more than 80% normal RNA, the vari-
ants will likely be benign andwill not contribute to the phenotype
in patients with STGD1. Similarly, there likely are thresholds for
moderately severe and severe alleles. However, as the clinical
Table 1. In vitro tested noncanonical splice site variants and their observed RNA and predicted protein effects
DNA variant RNA effect Protein effect
% correctly
spliced mRNA
Classification based
on RNA splice study
c.160+5G>C r.[=, 67_160del, 161_302delins(14)] p.[=, Ile23Alafs∗24, His55Asnfs∗63] 34,3 Moderate
c.161G>T r.161_302del p.(Cys54Serfs∗14) 0 Severe
c.302+4A>C r.161_302del p.(Cys54Serfs∗14) 0 Severe
c.303−3C>G r.[161_302delinsag, 302_303insag] p.[Cys54∗, Leu102Alafs∗14] 0 Severe
c.768G>T r.768_769ins(35) p.(Leu257Valfs∗17) 0 Severe
c.859−9T>C r.[=, 859_1356del] p.[=, Phe287_Arg452del] 75,7 Mild
c.1100−6T>A r.1099_1100insgcag p.(Thr367Serfs∗6) 0 Severe
c.1937+13T>G r.[1937_1938ins(12), =] p.[Phe647∗, =] 14# Severe
c.2382+5G>C∗ r.[=, 2161_2382del] p.[=, His721_Val794del] 47,9# Moderate
c.2588G>C∗ r.[2588g>c, 2588_2590delcag] p.[Gly863Ala, Gly863del] 60# Mild
c.2919−10T>C r.[=, 2919_3050del] p.[=, Leu973_His1017delinsPhe] 61,1 Moderate
c.2919−6C>A r.[=, 2919_3050del] p.[=, Leu973_His1017delinsPhe] 79,6 Mild
c.3050+5G>A r.2919_3050del p.(Leu973_His1017delinsPhe) 0 Severe
c.3522+5del r.[=, 3329_3522del] p.[=, Arg1111Aspfs∗7] 53,0 Moderate
c.3607G>A r.3523_3607del p.(Thr1176Metfs∗2) 10,9 Severe
c.3607+3A>T r.3523_3607del p.(Thr1176Metfs∗2) 0 Severe
c.3812A>G r.3608_3813del p.(Gly1203Aspfs∗10) 0 Severe
c.3813G>C r.3608_3813del p.(Gly1203Aspfs∗10) 0 severe
c.3862+3A>G r.[=, 3814_3862del] p.[=, Ile1272Valfs∗101] 53,4 Moderate
c.4128G>A r.4128_4129ins(12) p.(Gln1376_Ile1377ins4) 0 Severe
c.4253+4C>T r.4129_4253del p.(Ile1377Hisfs∗3) 7,8 Severe
c.4253+5G>A r.4129_4253del p.(Ile1377Hisfs∗3) 0 Severe
c.4253+5G>T r.[4129_4253del, =] p.[Ile1377Hisfs∗3, =] 5,4 Severe
c.4538A>G r.[4539_4540ins(30), 4467_4539del] p.[Arg1513_Arg1514ins10,
Cys1490Glufs∗12]
0$ Severe
c.4538A>C r.[4539_4540ins(30), 4467_4539del,
4538a>c]
p.[Pro1513_Arg1514ins10,
Cys1490Glufs∗12, Gln1513Pro]
4,3$ Severe
c.4634G>A r.4634g>a p.(Ser1545Asn) 100 Benign
c.4667G>C r.4635_4667del p.(Ser1545_Gln1555del) 0 Severe
c.4773G>C r.[4668_5018del, 4668_4773del] p.[Tyr1557_Val1673del,
Tyr1557Alafs∗18]
0 Severe
c.4773+3A>G r.[4668_4773del, =] p.[Tyr1557Alafs∗18, =] 24,6 Severe
c.4773+5G>A r.[4668_4773del, =, 4668_5018del] p.[Tyr1557Alafs∗18, =,
Tyr1557_Val1673del]
29,1 Severe
c.5196+3_5196+6del r.4849_5196del p.(Val1617_Ile1732del) 0 Severe
c.5196+3_5196+8del r.= p.(=) 100 Benign
c.5312+3A>T r.5197_5312del p.(Asn1734Glyfs∗14) 0 Severe
c.5313−3C>G r.5312_5313insag p.(Trp1772Aspfs∗7) 0 Severe
c.5460+5G>A r.5313_5460del p.(Trp1772Argfs∗9) 0 Severe
c.5461−10T>C r.5461_5714del p.(Thr1821Aspfs∗6) 0 Severe
c.5461−8T>G r.5461_5714del p.(Thr1821Aspfs∗6) 0 Severe
c.5584G>C r.5461_5714del p.(Thr1821Aspfs∗6) 0 Severe
c.5584+5G>A r.[5461_5714del, 5461_5584del] p.[Thr1821Aspfs∗6, Thr1821Valfs∗13] 0 Severe
c.5584+6T>C r.[5461_5714del, 5461_5584del] p.[Thr1821Aspfs∗6, Thr1821Valfs∗13,
Glu1863Leufs∗33]
0 Severe
c.5585−10T>C r.= p.(=) 100 Benign
c.5714+5G>A r.[=, 5585_5714del] p.[=, Glu1863Leufs∗33] 39,8 Moderate
c.5836−3C>A r.5835_5836ins(30) p.(Lys1945_Ile1946Pheins10) 0 Severe
c.5898+5del r.[5898_5899ins(494), 5898_5899ins
(170)]
p.(Cys1967Valfs∗24) 4,5 Severe
c.6478A>G r.[6478a>g, 6387_6479del] p.[Lys2160Glu,
Ser2129_Lys2160delinsArg]
55,2 Moderate
c.6479+4A>G r.6387_6479del p.(Ser2129_Lys2160delinsArg) 0 Severe
c.6729+5_6729
+19del
r.6480_6729del p.(Phe2161Cysfs∗3) 0 Severe
The nomenclature of all variants is according to the Human Genome Variation Society recommendations for the description of the sequence variants.
Complex effects at both the RNA and protein levels were included between square brackets. The products were listed according to their abundance
based on capillary electrophoresis-based analysis (Supplemental Table S3). For variants c.2382+5G>C and c.2588G>C, nomenclature does not include
the skipping of ABCA4 exon 15 (∗). The c.2588G>C variant previously was classified as a mild allele (Maugeri et al. 1999). For variants c.1937+13T>G
and c.2382+5G>C, the percentage of correctly spliced mRNA was determined by densitometry, and for variant c.2588G>C by direct analysis of Sanger
sequence traces (#). For variants c.4538A>C and c.4538A>G, the percentage of correctly spliced mRNA was not entirely determined due to likely comi-
grating gel fragments of similar size ($). (=) Wild type.
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data of patients carrying NCSS variants were not described consis-
tently, we could not accurately assign these thresholds. A similar
threshold model was recently described for the remaining normal
CEP290 protein in patients with Leber congenital amaurosis and
various syndromic phenotypes, as a result of different combina-
tions of coding and deep-intronic variants (Drivas et al. 2015).
The 29 BA constructs contain large (4.0–11.7 kb) segments of
ABCA4.We couldnot clone genomic fragments larger than 11.7 kb
due to the size constraint (12 kb) of the Gateway cloning system.
We therefore cloned introns 6 and 11 in different overlapping frag-
ments and performed transcript analysis using RHO primers.
Constructs containing the first and last exon were not generated
as they lack a splice acceptor and donor site, respectively. A diffi-
cult region to amplify was the 3′ part of the gene encompassing in-
tron 48–exon 50. The absence of both flanking ABCA4 exons
triggered splicing artifacts due to the presence of a strong RHO
splice donor and acceptor site, as we observed erroneous exon skip-
ping in MG_ex40 (Fig. 1).
Natural skipping of ABCA4 exons 3, 15, and 39/40 was ob-
served by others (Braun et al. 2013) and by us (Supplemental Fig.
S2), suggesting that the midigenes mimic the in vivo situation.
An accurate comparison of the skipping events for exons 3 and
39/40 between wild-typemidigene and human retina is not possi-
ble, as they result in frameshifts and the correspondingmRNAs are
subject to nonsense-mediated decay in the human retina.
Validatingmultiple splice products can be time-consuming as
gel-purification and Sanger sequencing are hampered by contam-
inations fromother fragments, thus requiring plasmid cloning and
additional Sanger sequencing. A more general drawback of the in
vitro splice assay is that, despite the observed splicing similarities
between wild-type BA clones and human retina, splicing in
HEK293T cells may not always mimic the splice defects as they
might occur in the retina of patients. Other studies have indicated
that indeed there are retina-specific splice factors (Murphy et al.
2016; Parfitt et al. 2016).
The use of bacterial artificial chromosome clones facilitated
the generation of large, multi-exon wild-type splice vectors. In
an alternative approach, a 5.6-kb BRCA1 minigene was construct-
ed by cloning six consecutive fragments carrying exons 19–27
that, in the human genome, span 28.7 kb (Acedo et al. 2015).
Our approach can readily be applied to generate midigenes from
all human genes, as BAC clones are available for this purpose
(https://bacpacresources.org/) (Osoegawa and de Jong 2004).
These wild-typemidigenes not only allow the accurate assessment
of large splice defects due to NCSS variants but can also be used to
test deep-intronic variants hypothesized to result in pseudo-exon
insertions (R Sangermano, A Garanto, M Khan, RWJ Collin, and
FPM Cremers, unpubl.).
We observed sizeable exon elongations in significantly occur-
ring RNA products due to c.160+5G>C, c.768G>T, c.1937+13T>G,
c.4538A>G, and c.4538A>C variants. Splice modulation using an-
tisense oligonucleotides (AONs) may be an option to redirect the
splicing back to the natural splice sites. AONs have already demon-
strated their therapeutic potential for several eye disease-associated
genes, such as CEP290 (Collin et al. 2012; Gerard et al. 2012;
Garanto et al. 2016; Parfitt et al. 2016), USH2A (Slijkerman et al.
2016), or OPA1 (Bonifert et al. 2016), and have a great potential
as therapeutic molecules for inherited retinal diseases.
In conclusion, we generated a complete set of sizeable wild-
type ABCA4 splice vectors, which allowed us to gain insight into
the severity of the poorly explored class of NCSS ABCA4 variants
on a gene-wide scale. By assessing the functional consequences
of putative splice defects, STGD1 patients can obtain a more accu-
rate molecular diagnosis and thereby become eligible for novel
therapies. Our approach can be used for all human genes to effec-
tively test putative splice defects. Besides from NCSS variants,
midigenes are also especially suited for testing rare deep-intronic
variants and their effect on splicing in a reliable manner, as 90%
of introns are <11 kb (Sakharkar et al. 2004) and thereby complete-
ly fit intomidigenes, together with all cis-acting splice factor bind-
ing motifs and flanked by their natural exons.
Methods
STGD1 patients
Patient 1 is a 40-yr-old female who was diagnosed with typical
STGD1 at the age of 16. Sanger sequence analysis of all 50
ABCA4 exons and a MLPA analysis (MRC Holland P151 and
P152) revealed heterozygous variants identified as two noncanon-
ical splice site variants, the previously described c.859−9T>C and
the novel c.303−3C>G. Patient 2 is a 37-yr-old male with STGD1
who was diagnosed at the age of 35 but had been suffering from
reduced visual acuity since the age of 22. Sanger sequence analysis
of all 50 ABCA4 exons revealed the coding variant c.70C>T
[p.(Arg24Cys)] and a novel intronic variant 13-bp downstream
from exon 13 (c.1937+13T>G). Patient 3 is a 53-yr-old female
with STGD1 who was diagnosed at the age of 49. Sanger sequence
analysis of all 50 ABCA4 exons revealed a novel homozygous
c.5461−8T>G variant. All three patients display extensive areas
of retinal pigment epithelium atrophy throughout the posterior
pole, extending beyond the vascular arcades. On electroretinogra-
phy, the cone and rod responses were significantly and equally re-
duced in patients 2 and 3 at the age of diagnosis.
Generation of wild-type and mutant minigenes for exons 39–41,
40, 48, and 49
Wild-type minigenes for exons 39–41, 40, 48, and 49 were gener-
ated by amplifying genomic DNA encompassing these exons
from genomic DNA of an anonymous control person. Mutant
minigenes for c.5714+5G>A and c.6729+5_+19del variants were
generated by amplifying these regions from the genomic DNA of
two patients carrying these ABCA4 variants. Primer details can
be found in Supplemental Tables S5 and S6. Minigenes were gen-
erated according to a previously described protocol (Sangermano
et al. 2016).
Generation of ABCA4 wild-type midigene library
The BACPAC Resource Center (BPRC) at the Children’s Hospital
Oakland Research Institute (Oakland, CA) provided the bacterial
artificial chromosome clone, CH17-325O16 (insert g.94,434,
639–94,670,492), containing the entire ABCA4 gene. Using
NucleoBond Xtra Midi EF (cat. no. 740420.250, Macherey-
Nagel), BAC DNA was isolated and used as a template to generate
large wild-type ABCA4 fragments by PCR. PCR primers were de-
signed using Primer3 software (http://bioinfo.ut.ee/primer3-0.4.0)
and their specificity verified by using Human BLAT searches
(https://genome.ucsc.edu/cgi-bin/hgBlat) (Kent 2002; Supple-
mental Table S6). PCR reaction mixtures (50 µL) contained 0.5
µM of each forward and reverse primer, 0.2 mM dNTPs, Phusion
High-Fidelity DNA Polymerase (cat. no. M0530L, New England
Biolabs), 1× Phusion GC Buffer, 3% DMSO, and 2.5 ng BAC
DNA. PCR reaction was performed by using the Veriti Thermal
Cycler (Thermo Fisher Scientific). All PCRs were performed using
the following thermocycling conditions: initial denaturation at
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98°C for 30 sec; 15–20 cycles of denaturation at 98°C for 10 sec
each, annealing at 57°C, and extension at 72°C (1 min/kb); with
a final extension at 72°C for 15 min. The PCR-amplified products
were analyzed on a 0.6% (w/v) agarose gel. Amplified bands were
excised, and the NucleoSpin Gel and PCR cleanup kit (cat. no.
740609.250, Macherey-Nagel) was used to purify the DNA frag-
ments, according to the manufacturer’s protocol.
Two hundred nanograms of each purified fragment were
cloned into the pDONR201 vector (Invitrogen) by using the
Gateway BP Clonase Enzyme Mix (cat. no. 11789021, Thermo
Fisher Scientific). The generated wild-type entry clones (denoted
Bacterial Artificial Chromosome ABCA4 [BA] clones) were digested
with restriction enzymes and validated by Sanger sequencing
(Supplemental Table S7), and each BA entry clone was transferred
into theGateway-adapted destination vector pCI-NEO-RHO as pre-
viously described (Sangermano et al. 2016).
Selection of candidate ABCA4 noncanonical splice site variants
Of the 47 ABCA4NCSS variants investigated in this study, 43 were
selected from the Leiden Open-source Variation Database (www.
LOVD.nl/ABCA4) (Cornelis et al. 2017), and three were found in
STGD1 patients (c.303−3C>G for patient 1, c.1937+13T>G for pa-
tient 2, c.5461−8T>G for patient 3) during routine diagnostic stud-
ies in the Radboudumc. c.2919−10T>C was a recently published
novel NCSS variant (Schulz et al. 2017). Forty-six of the NCSS
variants comply with the following three inclusion criteria: (1) lo-
cated in intronic positions −14 to −3 (splice acceptor site), or +3 to
+6 (splice donor site) or at the first or the last 2 nucleotides of
exons; (2) a reduction in the strength of the mutant splice site
compared to its wild-type reference when calculated by at least
one of five algorithms (SpliceSiteFinder-like, MaxEntScan,
NNSPLICE, GeneSplicer, Human Splicing Finder) (Shapiro and
Senapathy 1987; Reese et al. 1997; Pertea et al. 2001; Yeo and
Burge 2004; Desmet et al. 2009) via Alamut Visual software version
2.7 (Interactive Biosoftware; www.interactive-biosoftware.com);
and (3) an allele frequency of ≤0.005 in the gnomAD browser (ac-
cessed May 31, 2017) (Lek et al. 2016). Variant c.1937+13T>G is
not located in the splice donor site consensus sequence, and the
five splice prediction programs did not show any reductions in ca-
nonical and downstream splice sites. It was selected for a splice as-
say as it was the only rare intronic ABCA4 variant located outside
the NCSS consensus sequences but within 20 bp of an exon junc-
tion that was identified in routine Sanger sequencing of ∼300
STGD1 cases.
Generation of ABCA4 mutant constructs
Site-directed mutagenesis was performed on wild-type BA entry
clones as depicted in Figure 2. Mutagenesis primers were designed
by using the online tool QuikChange Primer Design (http://www.
genomics.agilent.com/primerDesignProgram.jsp?toggle=upload
Now&mutate=true&_requestid=1039517) and their GC content
and temperature verified by using the online software Multiple
Primer Analyzer (https://www.thermofisher.com/nl/en/home/
brands/thermo-scientific/molecular-biology/molecular-biology-
learning-center/molecular-biology-resource-library/thermo-scientific-
web-tools/multiple-primer-analyzer.html) (Supplemental Table
S8). The mutagenesis PCR reaction mixture (50 µL) contained
0.5 µM of each forward and reverse primer, 0.2 mM dNTPs, 1 U
Phusion High-Fidelity DNA Polymerase (cat. no. M0530L, New
England Biolabs), 1× Phusion HF Buffer, 2× Q-solution (cat. no.
1005485, Qiagen), and 20 ng wild-type entry clone. All PCRs
were performed using the following thermocycling conditions:
initial denaturation at 94°C for 5 min; 15 cycles of denaturation
at 94°C for 30 sec each, annealing between 55°C and 75°C, and ex-
tension at 72°C (1 min/kb), with a final extension at 72°C for 20
min. PCR-amplified productswere incubatedwithDpnI restriction
enzyme (cat. no. R0176S, New England Biolabs) for 4.5 hr, fol-
lowed by heat inactivation at 65°C for 20 min to remove the
wild-type plasmid DNA. Digested products were first run on a
0.6% (w/v) agarose gel to check for the presence of a unique linear
fragment, corresponding to the mutant construct. Each of the
NCSS variant mutants had their sequences validated (Supplemen-
tal Table S9), and finally, each validated mutant construct was
cloned into the Gateway-adapted destination vector pCI-NEO-
RHO as previously described (Sangermano et al. 2016).
In vitro splice assay and transcriptional analysis
To assess the effect of theNCSS variants on splicing, HEK293T cells
(CRL-3216, ATCC) were transfected with wild-type and mutant
constructs. Transfection, RNA isolation, and cDNA synthesis pro-
tocols were previously described (Sangermano et al. 2016).
ABCA4 transcript analysis was generally carried out by performing
RT-PCR analysis usingABCA4 exonic primers (Supplemental Table
S10). To test the effect of NCSS variants located in or near exons
that could not be flanked by other ABCA4 exons, e.g., due to the
large size of some introns, primers were used from RHO exons 3
and 5. RT-PCR using primers targeting RHO exon 5 was used as a
control for transfection efficiency (Supplemental Table S10).
All reactionmixtures (50 µL) contained 0.2 µMof each primer
pair, 1 U Taq DNA Polymerase (cat. no. 11647679001, Roche), 1×
PCR buffer with MgCl2, 1 mM MgCl2, 0.2 mM dNTPs, 1× Q-
Solution (cat. no. 1005485, Qiagen), and 50 ng cDNA. PCR condi-
tions were a first denaturation step of 94°C for 5 min, followed by
35 cycles of melting (94°C for 30 sec each), annealing (58°C for 30
sec), and extension (72°C for 5 min) steps, with a final elongation
step of 72°C for 2 min. The RT-PCR products were run on a 2%
(w/v) agarose gel and the resulting bandswere excised and purified
with the NucleoSpin Gel & PCR cleanup kit (cat. no. 740609.250,
Macherey-Nagel) according to the manufacturer’s protocol.
Finally, 100 ng of the purified nucleic acid were analyzed by
Sanger sequencing in a 3100 or 3730 DNA Analyzer (Thermo
Fisher Scientific). For complex RT-PCR band patterns, 4 µL of the
RT-PCRproducts, containing between 1 and 2µg ofDNA,were fur-
ther cloned via the pGEM-T Easy Vector System I (cat. no. A1360
Promega) according to the manufacturer’s protocol.
To determine the fraction of correctly spliced product, quan-
titative analysis of the RT-PCR bands was performed using the
Fragment Analyzer Auto Capillary Electrophoresis System
(Advanced Analytical Technologies, Inc.). RT-PCR of three con-
structs with no splice defects, 16 constructs with partial splice de-
fects, and three constructs with no correctly spliced RNAs were
performed in duplicate. Human retina cDNA was used as the con-
trol, as several ‘natural’ exon skipping events in human retina have
been reported previously (Supplemental Tables S3, S11; Supple-
mental Figs. S5, S6; Braun et al. 2013). For variants c.1937
+13G>T, c.2382+5G>C, and c.2588G>C, the fraction of correctly
spliced product was assessed by densitometric analysis using
Image J software (Schneider et al. 2012). The analysis was per-
formed in duplicate and values were normalized for the size of
the different fragments present in each RT-PCR product mixture
(Supplemental Table S12).
ABCA4 transcript analysis of patient-derived photoreceptor
precursor cells
Fibroblasts from a patient carrying the noncanonical splice site
variant c.768G>T in a homozygous state were successfully
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reprogrammed in iPSCs and further differentiated into photore-
ceptor precursor cells as previously described (Sangermano et al.
2016). Photoreceptor precursor cells were harvested, total RNA ex-
tracted, and RT-PCR performed by using a forward primer located
in ABCA4 exon 4 (5′-TCATGAATGCACCAGAGAGC-3′) and a
reverse primer located in ABCA4 exon 7 (5′-ACGGCTGTCTAG
GAGTGTGG-3′). Gel resolution, excision, and purification of the
bands and Sanger sequencing were performed as previously de-
scribed (Sangermano et al. 2016).
Data access
The raw sequencing data for all wild-type splicing constructs
(WT_BA), mutant splicing BA constructs (BA_c.), and RT-PCR frag-
ments (RT_BA) from splice assays in HEK293T cells from this study
have been submitted to the NCBI BioProject (https://www.ncbi.
nlm.nih.gov/bioproject/) under accession number PRJNA417900.
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